Investor overview

Synairgen is a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta candidate (SNG001) for COVID-19 and other severe lung infections​. UK-based and AIM listed, we were founded in 2003 as a spin-out from the University of Southampton.

SNG001 is a host-directed, broad-spectrum antiviral that directly targets the site of infection​ - the lungs. Its mode of action does not depend on a particular virus or variant.

Despite vaccination programmes and the availability of new therapeutics, thousands of patients are being hospitalised with COVID-19 every day. There is an urgent clinical need for new therapies to prevent the worsening of the disease, accelerate hospital discharge and enable patients to quickly return to usual activities​.

Results from the Phase 3 SPRINTER trial of SNG001 in hospitalised COVID-19 patients were announced in February 2022. SNG001 is currently being evaluated as part of the Phase 2 US NIH ACTIV-2 trial in home-based COVID-19 patients and, in October 2021, was recommended to advance into that trial’s larger follow-on Phase 3 study in mild to moderate COVID-19 patients. ​ Positive Phase 2 data, published in the Lancet Respiratory Medicine in 2020, established proof of principle for SNG001 in COVID-19.

FY21 Preliminary Results Presentation

Preliminary results for FY21

Investment Case

  • Pioneeringscience
  • Clinical Needlarge and growing
  • Experiencedleadership team
  • Wholly-ownedand novel investigative product
  • World-classpartners